A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Lorlatinib (Primary)
- Indications Anaplastic large cell lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms CRU3
- 16 Apr 2019 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
- 16 Apr 2019 Planned primary completion date changed from 10 Oct 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated